Five-year retrospective study of HER2+ breast cancer in a referral hospital in the state of Amazonas
Palavras-chave:
breast câncer, women, AmazonasResumo
Introduction: Breast carcinoma is considered the most common malignancy in women, with a high incidence in Brazil and in the North region, surpassed only by non-melanoma skin cancer and cervical cancer. The HER2+ molecular subtype tends to grow and spread more quickly than other subtypes, resulting in the second worst outcome, behind only the triple-negative subtype. Methods: This was a retrospective, descriptive epidemiological study, using data from the medical records of 192 patients with HER2+ breast cancer treated at the Fundação Centro de Controle de Oncologia do Amazonas (FCECON), from 2014 to 2018. Results: The mean age of patients was 52±12 years. The predominant origin was Manaus. AM (53.1%). The most common education level was complete secondary education (36.5%) and the occupation was self-employed (37%). Most diagnoses were made in 2014 (23.4%). Regarding staging, the most common ones were stages IIIA and IIIB, both 20.83%. Concerning treatment, all patients (100%) underwent radiotherapy and chemotherapy, and surgery in 80.2%, including mastectomy (58.33%) and quadrantectomy (21.87%). Local recurrence and distant metastasis were both found in 7.3% of patients. With respect to the outcome, patients in follow-up predominated (53.6%), while mortality rate was 0.5%. Conclusions: The series demonstrated that patients with HER2 breast cancer present advanced staging and undergo neoadjuvant chemotherapy and surgery. The center in the present study is an institution that receives patients from several municipalities in the countryside of Amazonas and other states, and thus, many patients with advanced stages are cared for, since many such cities have no resources to perform mammography, compromising screening.
Downloads
Referências
Santos M de O, Lima FC da S de, Martins LFL, Oliveira JFP, Almeida LM de, Cancela M de C. Estimativa de incidência de câncer no Brasil, 2023-2025. Rev. Bras. Cancerol. [Internet]. Feb. 2023; 69(1):e-213700. Available from https://rbc.inca.gov.br/index.php/revista/article/view/3700
Gomes RV, Rodrigues MÂ, Rodrigues JBSR, Vidigal PT, Damasceno KA, Lima HA, et al. Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival. Rev Col Bras Cir. 2018;45(3):e1826. https://doi.org/10.1590/0100-6991e-20181826
Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin. 2018;13(3):325-38. https://doi.org/10.1016/j.cpet.2018.02.004
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288-300. https://doi.org/10.1001/jama.2018.19323
Brasil. Ministéro da Saúde. Secretaria de Atenção à Saúde. Portaria Conjunta no 04, de 23 de janeiro de 2018. Aprova as Diretrizes Diagnósticas e Terapêuticas de Carcinoma de Mama [Internet]. Diário Oficial da União nº 193, de 06 de outubro de 2016, seção 1, página 38. [cited on 2023 Jan 23]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/sas/2018/poc0004_01_02_2018.html
Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. Expert Rev Clin Pharmacol. 2019;12(8):815-24. https://doi.org/10.1080/17512433.2019.1637252
Pereira HFBESA, Viapiana PS, Silva KLT. Aspectos clínicos e patológicos do câncer de mama em mulheres jovens atendidas na FCecon entre 2003 e 2013. Rev Bras Cancerol. 2019;63(2):103-9. https://doi.org/10.32635/2176-9745.RBC.2017v63n2.145
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364-82. https://doi.org/10.5858/arpa.2018-0902-SA
Hortobagyi GH, Connoly JL, D’orsi CJ, et al. Breast. In: American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Chicago: Springer; 2018. p.589-628.
R core team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2019 [cited on 2023 Jan. 25]. Available from: https://www.R-project.org/.
Yang X, Qu CX. Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study. Medicine (Batimore). 2022;101(25):e29371. https://doi.org/10.1097/MD.0000000000029371
Oliveira MF, Carvalho DS, Gonzalez AC, Trajano ETL. Estudo retrospectivo de pacientes diagnosticados com câncer de mama internados em hospital universitário. Rev Bras Mastologia. 2016;26(2):56-9. https://doi.org/10.5327/Z201600020005RBM
Fundação Centro de Controle de Oncologia do Amazonas. Relatório anual de gestão 2015 [Internet]. [cited on 2020 Feb 21]. Available from: http://www.fcecon.am.gov.br/wp-content/uploads/2016/05/Relatorio-fcecon-2015.pdf
Reis FP, Santos MEG, Sena WR, Santana R, Freitas TS, Silveira HF, et al. Perfil epidemiológico das pacientes com câncer de mama atendidas em uma unidade de saúde em São Francisco do Conde, Ba. Rev Ciênc Méd Biol. 2016;15(2):144-50. https://doi.org/10.9771/cmbio.v15i2.15194
Motoki AH. Associação entre a síndrome metabólica e o perfil imuno-histoquímico do câncer de mama em mulheres na pós-menopausa [dissertação]. Botucatu: Universidade Estadual Paulista; 2020.
Pinheiro RL, Monteiro GTR. Influência do índice de massa corporal na sobrevida de mulheres com diferentes subtipos de câncer de mama: uma revisão integrativa. Rev Bras Cancerol. 2019;65(2):e03373. https://doi.org/10.32635/2176-9745.RBC.2019v65n2.373
Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KD, Shao ZM. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among chinese women with breast cancer. PLoS One. 2012;7(7):e41380. https://doi.org/10.1371/journal.pone.0041380
Di Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res. 2020;22(1):115. https://doi.org/10.1186/s13058-020-01356-w
Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240-5. https://doi.org/10.1634/theoncologist.2012-0169
Lucia CPB. Perfil clínico epidemiológico de pacientes con cáncer de mama Her-2 positivo en el Hospital-III EsSalud José Cayetano Heredia-Piura 2013-2017. Universidad Privada Antenor Orrego [tese]. Perú: Universidad Privada Antenor Orrego; 2020.
Soares GP, Pereira AAL, Boas MSV, Vaisberg VV, Magalhães MCF, Linck RDM, et al. Value of systemic staging in asymptomatic early breast cancer. Rev Bras Ginecol Obstet. 2018;40(07):403-9. https://doi.org/10.1055/s-0038-1666997
Dagnoni C, Macedo LM, Argenti C, Januário JEA, Almeida TA, Skare NG. Perfil clínico e tumoral de pacientes submetidas a tratamento neoadjuvante de câncer de mama no Hospital Erasto Gaertner. Rev Bras Mastologia. 2016;26(4):158-63.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Lázara Gabriela Oliveira Silva, Hilka Flávia Barra do Espírito Santo Alves Pereira, Daniel dos Santos Moraes, Ligia Rebecca Mota Amorim, Luís Alexandre Lira de Castro
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
